An expert panel is slated the discuss the ongoing balancing act between the price of cancer drugs and the health benefits they bring for patients during the upcoming MedCity CONVERGE conference in Philadelphia, MedCity News reports.
The panel, “Value and Cost of Novel Cancer Treatments,” is set for June 19, and will feature:
- Jim Caggiano, Dendreon Pharmaceuticals CEO;
- Julie Kennerly-Shah, Ohio State University Comprehensive Cancer Center assistant director of pharmacy; and
- Hiroomi Tada, Notable Labs chief medical officer.
“It’s something that we’ve always struggled with,” Tada told MedCity News in an interview.